Biomea Fusion, Inc. (BMEA)
0.903
+0.07
(+7.96%)
USD |
NASDAQ |
Oct 16, 12:00
Biomea Fusion SG&A Expense (TTM) : 15.08M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.08M |
| March 31, 2026 | 16.17M |
| December 31, 2025 | 19.33M |
| September 30, 2025 | 20.56M |
| June 30, 2025 | 23.15M |
| March 31, 2025 | 25.52M |
| December 31, 2024 | 25.98M |
| September 30, 2024 | 27.61M |
| June 30, 2024 | 26.59M |
| March 31, 2024 | 25.24M |
| December 31, 2023 | 23.59M |
| September 30, 2023 | 22.86M |
| June 30, 2023 | 22.33M |
| Date | Value |
|---|---|
| March 31, 2023 | 21.51M |
| December 31, 2022 | 20.92M |
| September 30, 2022 | 18.83M |
| June 30, 2022 | 18.34M |
| March 31, 2022 | 16.66M |
| December 31, 2021 | 13.67M |
| September 30, 2021 | 10.02M |
| June 30, 2021 | 5.616M |
| March 31, 2021 | 2.484M |
| December 31, 2020 | 0.489M |
| September 30, 2020 | 0.489M |
| June 30, 2020 | 0.143M |
| March 31, 2020 | 0.064M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| REGENXBIO, Inc. | 85.56M |
| Compass Therapeutics, Inc. | 21.62M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |